



Corporate Press Release

8 November 2010

ACQUISITION OF SHARES IN PROSTRAKAN GROUP PLC

Norgine B.V. ("Norgine") announces that it has today acquired 25,515,873 shares in ProStrakan Group plc ("ProStrakan") representing 12.6 percent of the issued share capital of ProStrakan.

Whilst Norgine will continue to consider its options in relation to its holding in ProStrakan, for the purposes of Rule 2.8 of the City Code on Takeovers and Mergers (the "City Code"), it confirms that it has no current intention to make an offer for ProStrakan.

Pursuant to Rule 2.8 of the City Code, Norgine reserves the right to announce or participate in an offer or a possible offer to acquire the shares in ProStrakan which it does not already own and/or to take any other action which would otherwise be restricted under Rule 2.8 of the City Code within six months from the date of this announcement if there is a material change in circumstances or in the event that:

- (i) a third party exceeds a stake of 20 percent in the issued share capital of ProStrakan other than a shareholder that already holds more than 20 per cent. of the issued share capital; or
- (ii) there is an announcement of an offer or possible offer for ProStrakan by a third party; or
- (iii) ProStrakan announces a "whitewash" proposal (as described in Note 1 of the Notes on Dispensations from Rule 9 of the City Code).

Enquiries:

NORGINE B.V. Tel: +31 20 567 0900

Peter Stein (CEO)

Notes to Editors:

Norgine

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a direct presence in all the major European markets. Norgine employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas such as MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a new generation of bowel cleansing preparation and KLEAN-PREP[®] for bowel preparation prior to colonoscopy.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed in Wales and Dreux in France.

Norgine's website www.norgine.com